<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2024-2-95-102</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1568</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Системная красная волчанка с ювенильным началом: современное состояние проблемы (обзор литературы)</article-title><trans-title-group xml:lang="en"><trans-title>Systemic lupus erythematosus with juvenile onset: current status of the problem  (literature review)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0513-6826</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каледа</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaleda</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мария Игоревна Каледа</p><p>115522, Москва, Каширское шоссе, 34А</p><p>   </p></bio><bio xml:lang="en"><p>Maria Igorevna Kaleda</p><p>134A, Kashirskoe Shosse, Moscow 115522</p><p>   </p></bio><email xlink:type="simple">kaleda-mi@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1842-0348</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никишина</surname><given-names>И. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikishina</surname><given-names>I.  P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>134A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>22</day><month>04</month><year>2024</year></pub-date><volume>18</volume><issue>2</issue><fpage>95</fpage><lpage>102</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Каледа М.И., Никишина И.П., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Каледа М.И., Никишина И.П.</copyright-holder><copyright-holder xml:lang="en">Kaleda M.I., Nikishina I.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1568">https://mrj.ima-press.net/mrj/article/view/1568</self-uri><abstract><p>Больные системной красной волчанкой (СКВ) с ювенильным началом (юСКВ) составляют до 25% всех больных СКВ. Главное отличие юСКВ от СКВ у взрослых состоит в большей роли в ее возникновении генетических факторов, более высокой активности, раннем развитии осложнений и потребности в более агрессивной иммуносупрессивной терапии, что позволяет расценивать дебют заболевания в детском возрасте как особый фенотип СКВ. Актуальность изучения юСКВ определяется вариабельностью ее клинических проявлений и непредсказуемостью течения, трудностью ранней диагностики, быстрым развитием органных повреждений и неблагоприятным жизненным прогнозом.</p><p>В статье представлены наиболее значимые с практической точки зрения современные данные о диагностике, классификации, особенностях клинической картины и подходах к терапии юСКВ.</p></abstract><trans-abstract xml:lang="en"><p>Patients with juvenile-onset systemic lupus erythematosus (jSLE) account for up to 25% of all SLE patients. The main difference between jSLE and SLE in adults is the greater role of genetic factors in the pathogenesis, higher activity, earlier development of complications and the need for more aggressive immunosuppressive therapy, which allows us to consider the onset of the disease in childhood as a special phenotype of SLE. The relevance of the study of jSLE arises from the variability of clinical manifestations and the unpredictability of the course, the difficulty of early diagnosis, the rapid development of organ damage and the unfavorable life prognosis.</p><p>The article presents the most important modern data on the diagnosis, classification, features of the clinical picture and treatment approaches of jSLE from a practical point of view.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>системная красная волчанка с ювенильным началом</kwd><kwd>моногеннная волчанка</kwd><kwd>детский возраст</kwd></kwd-group><kwd-group xml:lang="en"><kwd>systemic lupus erythematosus with juvenile onset</kwd><kwd>monogenic lupus</kwd><kwd>childhood</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья подготовлена в рамках фундаментальной научной темы №1021051302580-4.</funding-statement><funding-statement xml:lang="en">The article was prepared within the framework of the basic scientific topic №1021051302580-4.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Levy DM, Kamphuis S. Systemic Lupus Erythematosus in Children and Adolescents. Pediatr Clin North Am. 2012 Apr;59(2):345-64. doi: 10.1016/j.pcl.2012.03.007.</mixed-citation><mixed-citation xml:lang="en">Levy DM, Kamphuis S. Systemic Lupus Erythematosus in Children and Adolescents. Pediatr Clin North Am. 2012 Apr;59(2):345-64. doi: 10.1016/j.pcl.2012.03.007.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Groot N, Shaikhani D, Teng YKO, et al. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Feb;71(2):290-301. doi: 10.1002/art.40697.</mixed-citation><mixed-citation xml:lang="en">Groot N, Shaikhani D, Teng YKO, et al. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Feb;71(2):290-301. doi: 10.1002/art.40697.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Асеева ЕА, Лила АМ, Соловьев СК и др.Клинико-иммунологические фенотипы системной красной волчанки, выделенные на основании кластерного анализа данных 400 пациентов ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой». Современная ревматология. 2022;16(5):13-21.</mixed-citation><mixed-citation xml:lang="en">Aseeva EA, Lila AM, Solov'ev SK, et al. Clinical and immunological phenotypes of systemic lupus erythematosus, identified based on cluster analysis of data from 400 patients from V.A. Nasonova Research Institute of Rheumatology. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2022; 16(5):13-21. (In Russ.)]. doi: 10.14412/1996-7012-2022-5-13-21</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Smith EMD, Lythgoe H, Midgley A, et al. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019 Dec:209:108274. doi: 10.1016/j.clim.2019.108274. Epub 2019 Oct 31.</mixed-citation><mixed-citation xml:lang="en">Smith EMD, Lythgoe H, Midgley A, et al. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019	Dec:209:108274. doi: 10.1016/j.clim.2019.108274. Epub 2019 Oct 31.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Huang JL, Yao TC, See LC. Prevalence ofpediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: a nation-wide prospective populationbased study in Taiwan. Clin Exp Rheumatol. 2004 Nov-Dec;22(6):776-80.</mixed-citation><mixed-citation xml:lang="en">Huang JL, Yao TC, See LC. Prevalence ofpediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: a nation-wide prospective populationbased study in Taiwan. Clin Exp Rheumatol. 2004 Nov-Dec;22(6):776-80.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Series OR. List of rare diseases and synonyms listed in alphabetical order: orphanet, 2021. http://www.orpha.net/orphacom/cahiers/docs/GB/List_of_rare_diseases_in_alphabetical_order.pdf</mixed-citation><mixed-citation xml:lang="en">Series OR. List of rare diseases and synonyms listed in alphabetical order: orphanet, 2021. http://www.orpha.net/orphacom/cahiers/docs/GB/List_of_rare_diseases_in_alphabetical_order.pdf</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Alexander T, Hedrich CM. Systemic lupuserythematosus – Are children miniature adults? Clin Immunol. 2022 Jan:234:108907. doi: 10.1016/j.clim.2021.108907. Epub 2021 Dec 8.</mixed-citation><mixed-citation xml:lang="en">Alexander T, Hedrich CM. Systemic lupuserythematosus – Are children miniature adults? Clin Immunol. 2022 Jan:234:108907. doi: 10.1016/j.clim.2021.108907. Epub 2021 Dec 8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) – Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017 Aug;31(4):488-504. doi: 10.1016/j.berh.2018.02.001. Epub 2018 Mar 1.</mixed-citation><mixed-citation xml:lang="en">Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) – Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017 Aug;31(4):488-504. doi: 10.1016/j.berh.2018.02.001. Epub 2018 Mar 1.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kwon YC, Chun S, Kim K, Mak A. Updateon the Genetics of Systemic Lupus Erythematosus: Genome-Wide Association Studies and Beyond. Cells. 2019 Sep 30;8(10):1180. doi: 10.3390/cells8101180.</mixed-citation><mixed-citation xml:lang="en">Kwon YC, Chun S, Kim K, Mak A. Updateon the Genetics of Systemic Lupus Erythematosus: Genome-Wide Association Studies and Beyond. Cells. 2019 Sep 30;8(10):1180. doi: 10.3390/cells8101180.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo CF, Grainge MJ, Valdes AM, et al. Familial Aggregation of Systemic Lupus Erythematosus and Coaggregation of Autoimmune Diseases in Affected Families. JAMA Intern Med. 2015 Sep;175(9):1518-26. doi: 10.1001/jamainternmed.2015.3528.</mixed-citation><mixed-citation xml:lang="en">Kuo CF, Grainge MJ, Valdes AM, et al. Familial Aggregation of Systemic Lupus Erythematosus and Coaggregation of Autoimmune Diseases in Affected Families. JAMA Intern Med. 2015 Sep;175(9):1518-26. doi: 10.1001/jamainternmed.2015.3528.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sestan M, Kifer N, Arsov T, et al The Roleof Genetic Risk Factors in Pathogenesis of Childhood-Onset Systemic Lupus Erythematosus. Curr Issues Mol Biol. 2023 Jul 17;45(7): 5981-6002. doi: 10.3390/cimb45070378.</mixed-citation><mixed-citation xml:lang="en">Sestan M, Kifer N, Arsov T, et al The Roleof Genetic Risk Factors in Pathogenesis of Childhood-Onset Systemic Lupus Erythematosus. Curr Issues Mol Biol. 2023 Jul 17;45(7): 5981-6002. doi: 10.3390/cimb45070378.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Caielli S, Wan Z, Pascual V. Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond. Annu Rev Immunol. 2023 Apr 26: 41:533-560. doi: 10.1146/annurev-immunol101921-042422. Epub 2023 Feb 28.</mixed-citation><mixed-citation xml:lang="en">Caielli S, Wan Z, Pascual V. Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond. Annu Rev Immunol. 2023 Apr 26: 41:533-560. doi: 10.1146/annurev-immunol101921-042422. Epub 2023 Feb 28.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ardoin SP, Daly RP, Merzoug L, et al;Childhood Arthritis and Rheumatology Research Alliance and Lupus Foundation of America. Research priorities in childhood-onset lupus: results of a multidisciplinary prioritization exercise. Pediatr Rheumatol Online J. 2019 Jul 1;17(1):32. doi: 10.1186/s12969-0190327-4.</mixed-citation><mixed-citation xml:lang="en">Ardoin SP, Daly RP, Merzoug L, et al;Childhood Arthritis and Rheumatology Research Alliance and Lupus Foundation of America. Research priorities in childhood-onset lupus: results of a multidisciplinary prioritization exercise. Pediatr Rheumatol Online J. 2019 Jul 1;17(1):32. doi: 10.1186/s12969-0190327-4.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Yu H, Nagafuchi Y, Fujio K. Clinical andImmunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules. 2021 Jun 22;11(7):928. doi: 10.3390/biom11070928.</mixed-citation><mixed-citation xml:lang="en">Yu H, Nagafuchi Y, Fujio K. Clinical andImmunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules. 2021 Jun 22;11(7):928. doi: 10.3390/biom11070928.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Li H, Wang T, Li B, et al. Bioinformaticanalysis of immune-related transcriptome affected by IFIT1 gene in childhood systemic lupus erythematosus. Transl Pediatr. 2023 Aug 30;12(8):1517-1526. doi: 10.21037/tp-23-365. Epub 2023 Aug 21.</mixed-citation><mixed-citation xml:lang="en">Li H, Wang T, Li B, et al. Bioinformaticanalysis of immune-related transcriptome affected by IFIT1 gene in childhood systemic lupus erythematosus. Transl Pediatr. 2023 Aug 30;12(8):1517-1526. doi: 10.21037/tp-23-365. Epub 2023 Aug 21.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ambrose N, Morgan TA, Galloway J, et al;UK JSLE Study Group. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016 Dec;25(14):1542-1550. doi: 10.1177/0961203316644333</mixed-citation><mixed-citation xml:lang="en">Ambrose N, Morgan TA, Galloway J, et al;UK JSLE Study Group. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016 Dec;25(14):1542-1550. doi: 10.1177/0961203316644333</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Oni L, Wright RD, Marks S, et al. Kidney outcomes for children with lupus nephritis. Pediatr Nephrol. 2021 Jun;36(6):1377-1385. doi: 10.1007/s00467-020-04686-1</mixed-citation><mixed-citation xml:lang="en">Oni L, Wright RD, Marks S, et al. Kidney outcomes for children with lupus nephritis. Pediatr Nephrol. 2021 Jun;36(6):1377-1385. doi: 10.1007/s00467-020-04686-1</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hsu TC, Yang YH, Wang LC, et al. Risk factors for subsequent lupus nephritis in patients with juvenile-onset systemic lupus erythematosus: a retrospective cohort study. Pediatr Rheumatol Online J. 2023 Mar 24;21(1):28. doi: 10.1186/s12969-023-00806-x</mixed-citation><mixed-citation xml:lang="en">Hsu TC, Yang YH, Wang LC, et al. Risk factors for subsequent lupus nephritis in patients with juvenile-onset systemic lupus erythematosus: a retrospective cohort study. Pediatr Rheumatol Online J. 2023 Mar 24;21(1):28. doi: 10.1186/s12969-023-00806-x</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chan EY, Lai FF, Ma AL, Chan TM. Managing Lupus Nephritis in Children and Adolescents. Paediatr Drugs. 2023 Dec 20. doi: 10.1007/s40272-023-00609-3. Online ahead of print.</mixed-citation><mixed-citation xml:lang="en">Chan EY, Lai FF, Ma AL, Chan TM. Managing Lupus Nephritis in Children and Adolescents. Paediatr Drugs. 2023 Dec 20. doi: 10.1007/s40272-023-00609-3. Online ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Appenzeller S, Pereira DR, Julio PR, et al. Neuropsychiatric manifestations in childhoodonset systemic lupus erythematosus. Lancet Child Adolesc Health. 2022 Aug;6(8):571-581. doi: 10.1016/S2352-4642(22)00157-2.</mixed-citation><mixed-citation xml:lang="en">Appenzeller S, Pereira DR, Julio PR, et al. Neuropsychiatric manifestations in childhoodonset systemic lupus erythematosus. Lancet Child Adolesc Health. 2022 Aug;6(8):571-581. doi: 10.1016/S2352-4642(22)00157-2.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023 Aug 9;10(1):5. doi: 10.1186/s40348-023-00161-7.</mixed-citation><mixed-citation xml:lang="en">Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023 Aug 9;10(1):5. doi: 10.1186/s40348-023-00161-7.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Каледа МИ, Никишина ИП, Глухова СИ, Степаненко НЮ. Нейропсихические нарушения при ювенильном дебюте системной красной волчанки: результаты ретроспективного исследования. Научно-практическая ревматология. 2020;58(2):171-177.</mixed-citation><mixed-citation xml:lang="en">Kaleda MI, Nikishina IP, Glukhova SI, Stepanenko NYu. Neuropsychic disorders in the juvenile onset of systemic lupus erythematosus: the results of a retrospective study. Nauchnoprakticheskaya revmatologiya. 2020;58(2): 171-177. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hiraki LT, Benseler SM, Tyrrell PN, et al.Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol. 2009 Nov;36(11): 2539-46. doi: 10.3899/jrheum.081141. Epub 2009 Oct 15.</mixed-citation><mixed-citation xml:lang="en">Hiraki LT, Benseler SM, Tyrrell PN, et al.Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol. 2009 Nov;36(11): 2539-46. doi: 10.3899/jrheum.081141. Epub 2009 Oct 15.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Watson L, Leone V, Pilkington C, et al;UK Juvenile-Onset Systemic Lupus Erythematosus Study Group. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum. 2012 Jul;64(7):2356-65. doi: 10.1002/art.34410.</mixed-citation><mixed-citation xml:lang="en">Watson L, Leone V, Pilkington C, et al;UK Juvenile-Onset Systemic Lupus Erythematosus Study Group. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum. 2012 Jul;64(7):2356-65. doi: 10.1002/art.34410.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Massias JS, Smith EMD, Al-Abadi E, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus. 2020 Apr;29(5):474481. doi: 10.1177/0961203320909156. Epub 2020 Mar 31.</mixed-citation><mixed-citation xml:lang="en">Massias JS, Smith EMD, Al-Abadi E, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus. 2020 Apr;29(5):474481. doi: 10.1177/0961203320909156. Epub 2020 Mar 31.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Massias JS, Smith EM, Al-Abadi E, et al.Clinical and laboratory phenotypes in juvenileonset Systemic Lupus Erythematosus across ethnicities in the UK. Lupus. 2021 Apr; 30(4):597-607. doi: 10.1177/0961203320984251. Epub 2021 Jan 7.</mixed-citation><mixed-citation xml:lang="en">Massias JS, Smith EM, Al-Abadi E, et al.Clinical and laboratory phenotypes in juvenileonset Systemic Lupus Erythematosus across ethnicities in the UK. Lupus. 2021 Apr; 30(4):597-607. doi: 10.1177/0961203320984251. Epub 2021 Jan 7.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Alperin JM, Ortiz-Fernandez L, Sawalha AH.Monogenic Lupus: A Developing Paradigm of Disease. Front Immunol. 2018 Oct 30:9:2496. doi: 10.3389/fimmu.2018.02496.eCollection 2018.</mixed-citation><mixed-citation xml:lang="en">Alperin JM, Ortiz-Fernandez L, Sawalha AH.Monogenic Lupus: A Developing Paradigm of Disease. Front Immunol. 2018 Oct 30:9:2496. doi: 10.3389/fimmu.2018.02496.eCollection 2018.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Harley ITW, Sawalha AH. Systemic lupuserythematosus as a genetic disease. Clin Immunol. 2022 Mar;236:108953. doi: 10.1016/j.clim.2022.108953</mixed-citation><mixed-citation xml:lang="en">Harley ITW, Sawalha AH. Systemic lupuserythematosus as a genetic disease. Clin Immunol. 2022 Mar;236:108953. doi: 10.1016/j.clim.2022.108953</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Misztal MC, Liao F, Couse M, et al. Genome-Wide Sequencing Identified Rare Genetic Variants for Childhood-Onset Monogenic Lupus. J Rheumatol. 2023 May;50(5):671-675. doi: 10.3899/jrheum.220513. Epub 2022 Nov 15.</mixed-citation><mixed-citation xml:lang="en">Misztal MC, Liao F, Couse M, et al. Genome-Wide Sequencing Identified Rare Genetic Variants for Childhood-Onset Monogenic Lupus. J Rheumatol. 2023 May;50(5):671-675. doi: 10.3899/jrheum.220513. Epub 2022 Nov 15.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Demirkaya E, Sahin S, Romano M, et al. New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond. J Clin Med. 2020 Mar 5;9(3):712. doi: 10.3390/jcm9030712.</mixed-citation><mixed-citation xml:lang="en">Demirkaya E, Sahin S, Romano M, et al. New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond. J Clin Med. 2020 Mar 5;9(3):712. doi: 10.3390/jcm9030712.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Mayouf SM, Alkhars F, AlSaleem A. Phenotype and disease course differences in monogenic and sporadic childhood lupus. Lupus. 2023 Nov;32(13):1548-1554. doi: 10.1177/09612033231211065. Epub 2023 Oct 25.</mixed-citation><mixed-citation xml:lang="en">Al-Mayouf SM, Alkhars F, AlSaleem A. Phenotype and disease course differences in monogenic and sporadic childhood lupus. Lupus. 2023 Nov;32(13):1548-1554. doi: 10.1177/09612033231211065. Epub 2023 Oct 25.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Belot A, Rice GI, Omarjee SO, et al; FREX Consortium; GENIAL Investigators; UK JSLE Study Group. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheumatol. 2020 Feb;2(2):e99-e109. doi: 10.1016/S2665-9913(19)30142-0. Epub 2020 Jan 13.9</mixed-citation><mixed-citation xml:lang="en">Belot A, Rice GI, Omarjee SO, et al; FREX Consortium; GENIAL Investigators; UK JSLE Study Group. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheumatol. 2020 Feb;2(2):e99-e109. doi: 10.1016/S2665-9913(19)30142-0. Epub 2020 Jan 13.9</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus. J Mol Med (Berl). 2016 Oct;94(10):1111-1127. doi: 10.1007/s00109016-1465-5. Epub 2016 Sep 27.</mixed-citation><mixed-citation xml:lang="en">Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus. J Mol Med (Berl). 2016 Oct;94(10):1111-1127. doi: 10.1007/s00109016-1465-5. Epub 2016 Sep 27.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020 Nov;146(5): 925-937. doi: 10.1016/j.jaci.2020.08.017.</mixed-citation><mixed-citation xml:lang="en">Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020 Nov;146(5): 925-937. doi: 10.1016/j.jaci.2020.08.017.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Sandling JK, Pucholt P, Hultin Rosenberg L, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis. 2021 Jan;80(1):109-117. doi: 10.1136/annrheumdis-2020-218636</mixed-citation><mixed-citation xml:lang="en">Sandling JK, Pucholt P, Hultin Rosenberg L, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis. 2021 Jan;80(1):109-117. doi: 10.1136/annrheumdis-2020-218636</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Mayouf SM, Alreefi HA, Alsinan TA, et al. Lupus manifestations in children with primary immunodeficiency diseases: Comprehensive phenotypic and genetic features and outcome. Mod Rheumatol. 2021 Nov;31(6): 1171-1178. doi: 10.1080/14397595.2021.1886627. Epub 2021 Feb 22.</mixed-citation><mixed-citation xml:lang="en">Al-Mayouf SM, Alreefi HA, Alsinan TA, et al. Lupus manifestations in children with primary immunodeficiency diseases: Comprehensive phenotypic and genetic features and outcome. Mod Rheumatol. 2021 Nov;31(6): 1171-1178. doi: 10.1080/14397595.2021.1886627. Epub 2021 Feb 22.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Sawada T, Fujimori D, Yamamoto Y. Systemic lupus erythematosus and immunodeficiency. Immunol Med. 2019 Mar;42(1):1-9. doi: 10.1080/25785826.2019.1628466. Epub 2019 Jun 17.</mixed-citation><mixed-citation xml:lang="en">Sawada T, Fujimori D, Yamamoto Y. Systemic lupus erythematosus and immunodeficiency. Immunol Med. 2019 Mar;42(1):1-9. doi: 10.1080/25785826.2019.1628466. Epub 2019 Jun 17.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Hoyt KJ, Chatila TA, Notarangelo LD, et al. The immunologic features of patients with early-onset and polyautoimmunity. Clin Immunol. 2020 Feb:211:108326. doi: 10.1016/j.clim.2019.108326. Epub 2019 Dec 12.</mixed-citation><mixed-citation xml:lang="en">Hoyt KJ, Chatila TA, Notarangelo LD, et al. The immunologic features of patients with early-onset and polyautoimmunity. Clin Immunol. 2020 Feb:211:108326. doi: 10.1016/j.clim.2019.108326. Epub 2019 Dec 12.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Sharifinejad N, Azizi G, Chavoshzadeh Z,et al. Autoimmunity in monogenic combined immune deficiencies with associated or syndromic features. Front Immunol. 2022 Dec 5:13: 1023127. doi: 10.3389/fimmu.2022.1023127.eCollection 2022.</mixed-citation><mixed-citation xml:lang="en">Sharifinejad N, Azizi G, Chavoshzadeh Z,et al. Autoimmunity in monogenic combined immune deficiencies with associated or syndromic features. Front Immunol. 2022 Dec 5:13: 1023127. doi: 10.3389/fimmu.2022.1023127.eCollection 2022.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Li YR, Li J, Zhao SD, et al. Meta-analysisof shared genetic architecture across ten pediatric autoimmune diseases. Nat Med. 2015 Sep;21(9):1018-27. doi: 10.1038/nm.3933. Epub 2015 Aug 24.</mixed-citation><mixed-citation xml:lang="en">Li YR, Li J, Zhao SD, et al. Meta-analysisof shared genetic architecture across ten pediatric autoimmune diseases. Nat Med. 2015 Sep;21(9):1018-27. doi: 10.1038/nm.3933. Epub 2015 Aug 24.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Molano-Gonzalez N, Rojas M, Monsalve DM, et al. Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J Autoimmun. 2019 Mar:98:24-32. doi: 10.1016/j.jaut.2018.11.002. Epub 2018 Nov 17.</mixed-citation><mixed-citation xml:lang="en">Molano-Gonzalez N, Rojas M, Monsalve DM, et al. Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J Autoimmun. 2019 Mar:98:24-32. doi: 10.1016/j.jaut.2018.11.002. Epub 2018 Nov 17.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Malagуn C, Gomez MDP, Mosquera C, et al. Juvenile polyautoimmunity in a rheumatology setting. Autoimmun Rev. 2019 Apr; 18(4):369-381. doi: 10.1016/j.autrev.2018.11.006. Epub 2019 Feb 14.</mixed-citation><mixed-citation xml:lang="en">Malagуn C, Gomez MDP, Mosquera C, et al. Juvenile polyautoimmunity in a rheumatology setting. Autoimmun Rev. 2019 Apr; 18(4):369-381. doi: 10.1016/j.autrev.2018.11.006. Epub 2019 Feb 14.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Setoue DN, Pitta AC, Fiorot FJ, et al; Brazilian Childhood-onset Systemic Lupus Erythematosus Group. Symptomatic polyautoimmunity at diagnosis of 1463 childhoodonset lupus: A Brazilian multicenter study. Autoimmun Rev. 2018 Aug;17(8):836-839. doi: 10.1016/j.autrev.2018.03.009. Epub 2018 Jun 7.</mixed-citation><mixed-citation xml:lang="en">Setoue DN, Pitta AC, Fiorot FJ, et al; Brazilian Childhood-onset Systemic Lupus Erythematosus Group. Symptomatic polyautoimmunity at diagnosis of 1463 childhoodonset lupus: A Brazilian multicenter study. Autoimmun Rev. 2018 Aug;17(8):836-839. doi: 10.1016/j.autrev.2018.03.009. Epub 2018 Jun 7.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Lythgoe H, Lj M, Hedrich CM, Aringer M.Classification of systemic lupus erythematosus in children and adults. Clin Immunol. 2022 Jan:234:108898. doi: 10.1016/j.clim.2021.108898. Epub 2021 Nov 29.</mixed-citation><mixed-citation xml:lang="en">Lythgoe H, Lj M, Hedrich CM, Aringer M.Classification of systemic lupus erythematosus in children and adults. Clin Immunol. 2022 Jan:234:108898. doi: 10.1016/j.clim.2021.108898. Epub 2021 Nov 29.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Batu ED, Akca UK, Kisaarslan AP, et al.The Performances of the ACR 1997, SLICC 2012, and EULAR/ACR 2019 Classification Criteria in Pediatric Systemic Lupus Erythematosus. J Rheumatol. 2021 Jun;48(6): 907-914. doi: 10.3899/jrheum.200871. Epub 2020 Nov 15.</mixed-citation><mixed-citation xml:lang="en">Batu ED, Akca UK, Kisaarslan AP, et al.The Performances of the ACR 1997, SLICC 2012, and EULAR/ACR 2019 Classification Criteria in Pediatric Systemic Lupus Erythematosus. J Rheumatol. 2021 Jun;48(6): 907-914. doi: 10.3899/jrheum.200871. Epub 2020 Nov 15.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Chang LS, Huang PY, Kuo HC, et al. Diagnostic accuracy of the American College of Rheumatology-1997, the Systemic Lupus International Collaborating Clinics-2012, and the European League Against Rheumatism2019 criteria for juvenile systemic lupus erythematosus: A systematic review and network meta-analysis. Autoimmun Rev. 2022 Sep; 21(9):103144. doi: 10.1016/j.autrev.2022.103144. Epub 2022 Jul 13.</mixed-citation><mixed-citation xml:lang="en">Chang LS, Huang PY, Kuo HC, et al. Diagnostic accuracy of the American College of Rheumatology-1997, the Systemic Lupus International Collaborating Clinics-2012, and the European League Against Rheumatism2019 criteria for juvenile systemic lupus erythematosus: A systematic review and network meta-analysis. Autoimmun Rev. 2022 Sep; 21(9):103144. doi: 10.1016/j.autrev.2022.103144. Epub 2022 Jul 13.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Ohara A, Iwata N, Sugiura S, et al. Evaluation of the European League Against Rheumatism/American College of Rheumatology-2019 classification criteria in patients with childhood-onset systemic lupus erythematosus: a single-center retrospective study. Clin Rheumatol. 2022 Aug;41(8):2483-2489. doi: 10.1007/s10067-022-06138-7. Epub 2022 Apr 4.</mixed-citation><mixed-citation xml:lang="en">Ohara A, Iwata N, Sugiura S, et al. Evaluation of the European League Against Rheumatism/American College of Rheumatology-2019 classification criteria in patients with childhood-onset systemic lupus erythematosus: a single-center retrospective study. Clin Rheumatol. 2022 Aug;41(8):2483-2489. doi: 10.1007/s10067-022-06138-7. Epub 2022 Apr 4.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Mayouf SM, Akbar L, Abdwani R, et al. Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematous in monogenic lupus. Clin Rheumatol. 2022 Sep;41(9):2721-2727. doi: 10.1007/s10067-022-06209-9. Epub 2022 May 19.</mixed-citation><mixed-citation xml:lang="en">Al-Mayouf SM, Akbar L, Abdwani R, et al. Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematous in monogenic lupus. Clin Rheumatol. 2022 Sep;41(9):2721-2727. doi: 10.1007/s10067-022-06209-9. Epub 2022 May 19.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Brunner HI, Huggins J, Klein-Gitelman MS. Pediatric SLE-towards a comprehensive management plan. Nat Rev Rheumatol. 2011 Apr;7(4):225-33. doi: 10.1038/nrrheum.2011.15. Epub 2011 Mar 8.</mixed-citation><mixed-citation xml:lang="en">Brunner HI, Huggins J, Klein-Gitelman MS. Pediatric SLE-towards a comprehensive management plan. Nat Rev Rheumatol. 2011 Apr;7(4):225-33. doi: 10.1038/nrrheum.2011.15. Epub 2011 Mar 8.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Aragon E, Resontoc LP, Chan YH, et al. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis. Lupus. 2016 Apr;25(4):399-406. doi: 10.1177/0961203315 615220. Epub 2015 Nov 3.</mixed-citation><mixed-citation xml:lang="en">Aragon E, Resontoc LP, Chan YH, et al. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis. Lupus. 2016 Apr;25(4):399-406. doi: 10.1177/0961203315 615220. Epub 2015 Nov 3.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Smith EMD, Tharmaratnam K, Al-Abadi E,et al. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology (Oxford). 2022 Aug 3;61(8):33783389. doi: 10.1093/rheumatology/keab915.</mixed-citation><mixed-citation xml:lang="en">Smith EMD, Tharmaratnam K, Al-Abadi E,et al. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology (Oxford). 2022 Aug 3;61(8):33783389. doi: 10.1093/rheumatology/keab915.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Chen YC, Hsu CY, Tsai MC, et al. Remission and long-term remission of pediatric-onset systemic lupus erythematosus. Front Pediatr. 2023 Oct 27:11:1272065. doi: 10.3389/fped.2023.1272065. eCollection 2023.</mixed-citation><mixed-citation xml:lang="en">Chen YC, Hsu CY, Tsai MC, et al. Remission and long-term remission of pediatric-onset systemic lupus erythematosus. Front Pediatr. 2023 Oct 27:11:1272065. doi: 10.3389/fped.2023.1272065. eCollection 2023.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Falcini F, Nacci F. Systemic lupus erythematosus in the young: the importance of a transition clinic. Lupus. 2007;16(8):613-7. doi: 10.1177/0961203307078973.</mixed-citation><mixed-citation xml:lang="en">Falcini F, Nacci F. Systemic lupus erythematosus in the young: the importance of a transition clinic. Lupus. 2007;16(8):613-7. doi: 10.1177/0961203307078973.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Groot N, de Graeff N, Avcin T, et al.European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017 Nov;76(11): 1788-1796. doi: 10.1136/annrheumdis-2016210960. Epub 2017 Jun 19.</mixed-citation><mixed-citation xml:lang="en">Groot N, de Graeff N, Avcin T, et al.European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017 Nov;76(11): 1788-1796. doi: 10.1136/annrheumdis-2016210960. Epub 2017 Jun 19.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Gutierrez-Suarez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006 Sep; 54(9):2989-96. doi: 10.1002/art.22048.</mixed-citation><mixed-citation xml:lang="en">Gutierrez-Suarez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006 Sep; 54(9):2989-96. doi: 10.1002/art.22048.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Ozturk K, Caglayan S, Tanatar A, et al;PeRA-Research Group. Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus. 2021 Nov;30(13):2144-2150. doi: 10.1177/09612033211054399. Epub 2021 Nov 1.</mixed-citation><mixed-citation xml:lang="en">Ozturk K, Caglayan S, Tanatar A, et al;PeRA-Research Group. Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus. 2021 Nov;30(13):2144-2150. doi: 10.1177/09612033211054399. Epub 2021 Nov 1.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Na Nakorn K, Piyaphanee N, Sukharomana M, et al. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus. Clin Rheumatol. 2023 Jun;42(6):16551664. doi: 10.1007/s10067-023-06533-8. Epub 2023 Feb 13.</mixed-citation><mixed-citation xml:lang="en">Na Nakorn K, Piyaphanee N, Sukharomana M, et al. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus. Clin Rheumatol. 2023 Jun;42(6):16551664. doi: 10.1007/s10067-023-06533-8. Epub 2023 Feb 13.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Bao S, Huang H, Jin Y, et al. Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus. Lupus Sci Med. 2023 Apr;10(1): e000834. doi: 10.1136/lupus-2022-000834.</mixed-citation><mixed-citation xml:lang="en">Bao S, Huang H, Jin Y, et al. Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus. Lupus Sci Med. 2023 Apr;10(1): e000834. doi: 10.1136/lupus-2022-000834.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhoodonset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017 Dec;76(12):1965-1973. doi: 10.1136/annrheumdis-2017-211898. Epub 2017 Sep 6.</mixed-citation><mixed-citation xml:lang="en">Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhoodonset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017 Dec;76(12):1965-1973. doi: 10.1136/annrheumdis-2017-211898. Epub 2017 Sep 6.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017 Oct;76(10):16371641. doi: 10.1136/annrheumdis-2016211001. Epub 2017 May 4.</mixed-citation><mixed-citation xml:lang="en">Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017 Oct;76(10):16371641. doi: 10.1136/annrheumdis-2016211001. Epub 2017 May 4.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева ЕИ, Дворяковская ТМ, Никишина ИП и др. Системная красная волчанка: клинические рекомендации. Часть 2. Вопросы современной педиатрии. 2018;17(2):110-25.</mixed-citation><mixed-citation xml:lang="en">Alekseeva EI, Dvoryakovskaya TM, Nikishina IP, et al. Systemic lupus erythematosus: clinical recommendations. Part 2. Voprosy sovremennoi pediatrii. 2018;17(2):110-25. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun; 78(6):736-745. doi: 10.1136/annrheumdis2019-215089. Epub 2019 Mar 29.</mixed-citation><mixed-citation xml:lang="en">Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun; 78(6):736-745. doi: 10.1136/annrheumdis2019-215089. Epub 2019 Mar 29.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs. 2021 Jul; 23(4):331-347. doi: 10.1007/s40272-02100457-z. Epub 2021 Jul 10.</mixed-citation><mixed-citation xml:lang="en">Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs. 2021 Jul; 23(4):331-347. doi: 10.1007/s40272-02100457-z. Epub 2021 Jul 10.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Hammam N, Evans M, Bell CF, et al. Evaluating the Use of Glucocorticoids Among Belimumab-Treated Patients With Systemic Lupus Erythematosus in Real-World Settings Using the Rheumatology Informatics System for Effectiveness Registry. ACR Open Rheumatol. 2022 Oct;4(10):883-889. doi: 10.1002/acr2.11482. Epub 2022 Jul 24.</mixed-citation><mixed-citation xml:lang="en">Hammam N, Evans M, Bell CF, et al. Evaluating the Use of Glucocorticoids Among Belimumab-Treated Patients With Systemic Lupus Erythematosus in Real-World Settings Using the Rheumatology Informatics System for Effectiveness Registry. ACR Open Rheumatol. 2022 Oct;4(10):883-889. doi: 10.1002/acr2.11482. Epub 2022 Jul 24.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Chen F, Zheng Y, Chen X, et al. Belimumab in childhood systemic lupus erythematosus: A review of available data. Front Immunol. 2022 Jul 27:13:940416. doi: 10.3389/fimmu.2022.940416. eCollection 2022.</mixed-citation><mixed-citation xml:lang="en">Chen F, Zheng Y, Chen X, et al. Belimumab in childhood systemic lupus erythematosus: A review of available data. Front Immunol. 2022 Jul 27:13:940416. doi: 10.3389/fimmu.2022.940416. eCollection 2022.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Lim LSH, Pullenayegum E, Lim L, et al.From childhood to adulthood: the trajectory of damage in patients with juvenile-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1627-1635. doi: 10.1002/acr.23199. Epub 2017 Sep 26.</mixed-citation><mixed-citation xml:lang="en">Lim LSH, Pullenayegum E, Lim L, et al.From childhood to adulthood: the trajectory of damage in patients with juvenile-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1627-1635. doi: 10.1002/acr.23199. Epub 2017 Sep 26.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Smith E, Al-Abadi E, Armon K, et al.Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus. 2019 Apr;28(5):613-620. doi: 10.1177/0961203319836712. Epub 2019 Mar 14.</mixed-citation><mixed-citation xml:lang="en">Smith E, Al-Abadi E, Armon K, et al.Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus. 2019 Apr;28(5):613-620. doi: 10.1177/0961203319836712. Epub 2019 Mar 14.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Brunner HI, Vadhariya A, Dickson C, et al.Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Sci Med. 2023 Jul; 10(2):e000817. doi: 10.1136/lupus-2022000817.</mixed-citation><mixed-citation xml:lang="en">Brunner HI, Vadhariya A, Dickson C, et al.Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Sci Med. 2023 Jul; 10(2):e000817. doi: 10.1136/lupus-2022000817.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Mao Y, Yin L, Huang H, et al. Addition ofcyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy. J Int Med Res. 2019 Jan; 47(1):105-113. doi: 10.1177/0300060518796751. Epub 2018 Sep 12.</mixed-citation><mixed-citation xml:lang="en">Mao Y, Yin L, Huang H, et al. Addition ofcyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy. J Int Med Res. 2019 Jan; 47(1):105-113. doi: 10.1177/0300060518796751. Epub 2018 Sep 12.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Jansson AF, Sengler C, KuemmerleDeschner J, et al. B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol. 2011 Jan;30(1):87-97. doi: 10.1007/s10067-010-1630-0. Epub 2010 Dec 1.</mixed-citation><mixed-citation xml:lang="en">Jansson AF, Sengler C, KuemmerleDeschner J, et al. B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol. 2011 Jan;30(1):87-97. doi: 10.1007/s10067-010-1630-0. Epub 2010 Dec 1.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Merino-Vico A, Frazzei G, van Hamburg JP,Tas SW. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches. Eur J Immunol. 2023 Jan;53(1):e2149675. doi: 10.1002/eji.202149675. Epub 2022 Nov 16.</mixed-citation><mixed-citation xml:lang="en">Merino-Vico A, Frazzei G, van Hamburg JP,Tas SW. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches. Eur J Immunol. 2023 Jan;53(1):e2149675. doi: 10.1002/eji.202149675. Epub 2022 Nov 16.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Бекетова ТВ, Ананьева ЛПи др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. [</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Beketova TV, Anan'eva LP, et al. Prospects of anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-prakticheskaya revmatologiya. 2019; 57:1-40. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Mahmoud I, Jellouli M, Boukhris I, et al.Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. J Pediatr. 2017 Aug:187:213-219.e2. doi: 10.1016/j.jpeds.2017.05.002.</mixed-citation><mixed-citation xml:lang="en">Mahmoud I, Jellouli M, Boukhris I, et al.Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. J Pediatr. 2017 Aug:187:213-219.e2. doi: 10.1016/j.jpeds.2017.05.002.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Sawhney S, Agarwal M. Rituximab use inpediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. Lupus. 2021 Oct;30(11):1829-1836. doi: 10.1177/09612033211034567. Epub 2021 Jul 27.</mixed-citation><mixed-citation xml:lang="en">Sawhney S, Agarwal M. Rituximab use inpediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. Lupus. 2021 Oct;30(11):1829-1836. doi: 10.1177/09612033211034567. Epub 2021 Jul 27.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Каледа МИ, Никишина ИП, Николаева ЕВ и др. Ритуксимаб при ревматических заболеваниях у детей: результаты ретроспективного исследования безопасности терапии. Научно-практическая ревматология. 2021;59(2):208-214</mixed-citation><mixed-citation xml:lang="en">Kaleda MI, Nikishina IP, Nikolaeva EV, et al. Rituximab for rheumatic diseases in children: results of a retrospective study of the safety of therapy. Nauchno-prakticheskaya revmatologiya. 2021;59(2):208-214. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Cinar OK, Marlais M, Al Obaidi M, et al. Ofatumumab use in juvenile systemic lupus erythematosus: A single centre experience. Lupus. 2021 Mar;30(3):527-530. doi: 10.1177/0961203320981137</mixed-citation><mixed-citation xml:lang="en">Cinar OK, Marlais M, Al Obaidi M, et al. Ofatumumab use in juvenile systemic lupus erythematosus: A single centre experience. Lupus. 2021 Mar;30(3):527-530. doi: 10.1177/0961203320981137</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Lei L, Muhammad S, Al-Obaidi M, et al. Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase Cδ. Pediatr Rheumatol Online J. 2018 Sep 26;16(1): 61. doi: 10.1186/s12969-018-0278-1.</mixed-citation><mixed-citation xml:lang="en">Lei L, Muhammad S, Al-Obaidi M, et al. Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase Cδ. Pediatr Rheumatol Online J. 2018 Sep 26;16(1): 61. doi: 10.1186/s12969-018-0278-1.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021; 59(4):367-383.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-prakticheskaya revmatologiya. 2021;59(4):367-383. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Guzman M, Hui-Yuen JS. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab. Drug Des Devel Ther. 2020 Jun 25:14:2503-2513. doi: 10.2147/DDDT.S216193.eCollection 2020.</mixed-citation><mixed-citation xml:lang="en">Guzman M, Hui-Yuen JS. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab. Drug Des Devel Ther. 2020 Jun 25:14:2503-2513. doi: 10.2147/DDDT.S216193.eCollection 2020.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Brunner HI, Abud-Mendoza C, Viola DO, et al; Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020 Oct;79(10):1340-1348. doi: 10.1136/annrheumdis-2020-217101. Epub 2020 Jul 22.</mixed-citation><mixed-citation xml:lang="en">Brunner HI, Abud-Mendoza C, Viola DO, et al; Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020 Oct;79(10):1340-1348. doi: 10.1136/annrheumdis-2020-217101. Epub 2020 Jul 22.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. J Rheumatol. 2014 Apr; 41(4):759-67. doi: 10.3899/jrheum.130690. Epub 2014 Mar 15.</mixed-citation><mixed-citation xml:lang="en">Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. J Rheumatol. 2014 Apr; 41(4):759-67. doi: 10.3899/jrheum.130690. Epub 2014 Mar 15.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Ramaswamy M, Tummala R, Streicher K,et al. The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases. Int J Mol Sci. 2021 Oct 19;22(20):11286. doi: 10.3390/ijms222011286.</mixed-citation><mixed-citation xml:lang="en">Ramaswamy M, Tummala R, Streicher K,et al. The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases. Int J Mol Sci. 2021 Oct 19;22(20):11286. doi: 10.3390/ijms222011286.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Shaw KS, Rajeh A, Le T, et al. Anifrolumab for Adolescent Discoid Lupus Erythematosus. JAMA Netw Open. 2023 Oct 2;6(10): e2338200. doi: 10.1001/jamanetworkopen.2023.38200.</mixed-citation><mixed-citation xml:lang="en">Shaw KS, Rajeh A, Le T, et al. Anifrolumab for Adolescent Discoid Lupus Erythematosus. JAMA Netw Open. 2023 Oct 2;6(10): e2338200. doi: 10.1001/jamanetworkopen.2023.38200.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Pin A, Tesser A, Pastore S, Moressa V, et al. Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors. Int J Mol Sci. 2020 Oct 20;21(20): 7767. doi: 10.3390/ijms21207767.</mixed-citation><mixed-citation xml:lang="en">Pin A, Tesser A, Pastore S, Moressa V, et al. Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors. Int J Mol Sci. 2020 Oct 20;21(20): 7767. doi: 10.3390/ijms21207767.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Chuprin J, McCormack L, Richmond JM,Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update. Expert Rev Clin Immunol. 2022 Mar;18(3):263-272. doi: 10.1080/1744666X.2022.2047022. Epub 2022 Mar 4.</mixed-citation><mixed-citation xml:lang="en">Chuprin J, McCormack L, Richmond JM,Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update. Expert Rev Clin Immunol. 2022 Mar;18(3):263-272. doi: 10.1080/1744666X.2022.2047022. Epub 2022 Mar 4.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Rossano M, Conti EA, Bocca P, et al. Novel heterozygous TREX1 mutation in a juvenile systemic lupus erythematosus patient with severe cutaneous involvement treated successfully with Jak-inhibitors: a case report. Front Immunol. 2023 Dec 6:14:1288675. doi: 10.3389/fimmu.2023.1288675.eCollection 2023.</mixed-citation><mixed-citation xml:lang="en">Rossano M, Conti EA, Bocca P, et al. Novel heterozygous TREX1 mutation in a juvenile systemic lupus erythematosus patient with severe cutaneous involvement treated successfully with Jak-inhibitors: a case report. Front Immunol. 2023 Dec 6:14:1288675. doi: 10.3389/fimmu.2023.1288675.eCollection 2023.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
